

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Egidijus Edward Uzgis et al. : Group Art Unit:

Serial No.: : Examiner:

Filed: :

For MAGNETIC RESONANCE
CONTRAST-ENHANCING AGENTS AND
METHOD FOR DETECTING AND IMAGING
ARTHEROSCLEROTIC PLAQUE :

INFORMATION DISCLOSURE STATEMENT

- ☒ 1 **Pursuant to 37CFR 1.97(b)**
[within 3 months of national, non-CPA filing or prior to 1st Office Action] *no charge*
- ☐ 2 **Certification Pursuant to 37 CFR 1.97(c)(1)**
[before Final Office Action, Allowance, or other action closing prosecution] *no charge*
- ☐ 3 **Fee Payment Pursuant to 37 CFR 1.97(c)(2)**
[before Final Office Action, Allowance, or other action closing prosecution] *\$180.00*
- ☐ 4 **Certification & Fee Payment Pursuant to 37 CFR 1.97(d)**
[On or before issue fee payment] *\$180.00*

ATTN: BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The following are submitted in the above application in compliance with 37 CFR 1.97 and 37 CFR 1.98:

- ☒ 5 A list of documents on form PTO-1449 or Substitute together with copies of each identified document and a translation thereof or a concise explanation of each non-English language document or a Search Report from an International Searching Authority for a patent application filed via the Patent Cooperation Treaty or document(s) cited in the application or the priority application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date of Deposit_____
Type or Print Name_____
Signature

This paper is submitted in accordance with:

- ☒ 6 37 CFR 1.97(b): [within 3 months of national, non-CPA filing or prior to 1st Office Action]
- ☐ 7 37 CFR 1.97(c): [before Final Office Action, Allowance, or other action closing prosecution, whichever is earlier]; and
- ☐ 8 The required Certification made in item 11 below; or
- ☐ 9 The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 15 below.
- ☐ 10 37 CFR 1.97(d): [on or before issue fee payment]; and
- a) The required Certification is stated in item 11 below; and
- b) The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 14 below.
- ☐ 11 Certification
- ☐ 12 Each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this Statement; or
- ☐ 13 No item contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this document after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing date of this Statement.
- ☒ 14 Payment of all applicable fees:
- ☒ 15 Please charge all applicable fees associated with the submittal of this Information Disclosure Statement to Deposit Account No. 07-0868

An original and two (2) copies of this document are enclosed.

June 26, 2003

Date

General Electric Company
CRD Patent Department 4A59
P.O. Box 8, Bldg. K-1
Schenectady, New York 12301
Customer Number: 006147

Respectfully submitted,

Toan P. Vo

Attorney - Toan P. Vo

Registration No. 43,225

Phone: (518) 387-6648

or (518) 387-7122

FORM PTO-1449
(REV. 7-80)
(Title Amended 3/83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

125478-1

SERIAL NO.

Applicant

Egidijus Edward Uzgis et al.

Filing Date

Group

INFORMATION DISCLOSURE STATEMENT BY APPLICANT--

LIST OF ITEMS

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 5 7 6 2 9 0 9	06/09/98	Uzgis			
	AB 6 2 3 5 2 6 4	05/22/01	Usgiris			
	AC 5 6 8 1 5 4 2	10/28/97	Unger			
	AD 5 5 1 6 5 0 3	05/14/96	Bourgouin et al.			
	AE 5 2 4 2 6 8 3	09/07/93	Klaveness			
	AF 6 2 4 1 9 6 8	06/05/01	Tournier et al.			
	AG 4 6 8 7 6 5 9	08/18/87	Quay			
	AH 4 9 0 9 2 5 7	03/20/90	Engelstad et al.			
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	No
AL							
AM							
AN							
AO							
AP							

OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc.)

AR	
AS	
AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) (Title Amended 3/83) INFORMATION DISCLOSURE STATEMENT BY APPLICANT-- <u>LIST OF ITEMS</u> (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 125478-1	SERIAL NO.
		Applicant Egidijus Edward Uzgis et al.	
		Filing Date	Group

OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc)

	AU	US 2002/0094316 A1 Patent Application Publication, S. Liu, "Polypodal Chelants for Metallopharmaceuticals", Serial Number 10/033,769, Filed December 27, 2001.
	AV	↓ Patent Application Serial Number 10/209,726, "Improved Syntheses of Highly Conjugated Polymers", Filed July 31, 2002, Bahram Moasser et al., Docket Number RD-29,473.
	AW	✓ Patent Application Serial Number 09/803,794, "Medical Imaging Method for Characterizing Tumor Angiogenesis Using Polymeric Contrast Agents", Filed March 12, 2001, Egidijus E. Uzgis et al., Docket Number RD-26797-5.
	AX	↓ P. Libby, "Atherosclerosis: The New View," Scientific American, 47-55, (May 2002).
✓	AY	W. Kerwin et al., "Quantitative Magnetic Resonance Imaging Analysis of Neovasculture Volume in Carotid Atherosclerotic Plaques," Circulation, (February 18, 2003).
✓	AZ	B. A. Wasserman et al., "Carotid Artery Atherosclerosis: In Vivo Morphologic Characterization with Gadolinium-Enhanced Double Oblique MR Imaging - Initial Results," Radiology, Volume 223, No. 2, 566-573, (2002).
✓	BU	C. Yuan et al., "Contrast Enhanced High Resolution MRI for Atherosclerotic Carotid Artery Tissue Characterization," Journal of Magnetic Resonance Imaging, Vol. 15, 62-67, (2002).
✓	BV	J. F. Toussaint, "Magnetic Resonance Images Lipid, Fibrous, Calcified, Hemorrhagic and Thrombotic Components of Human Atherosclerosis In Vivo," Circulation, Vol. 94, 932 (1996).
✓	BW	C. Yuan et al., "Measurement of Atherosclerotic Carotid Plaque Size in Vivo Using High Resolution Magnetic Resonance Imaging", Circulation, Vol. 98, 2666-2671, (1998).
	BX	S. Aoki, "Dynamic MR Imaging of the Carotid Wall," Journal of Magnetic Resonance Imaging, Vol. 9, 420 (1999).
✓	BY	S. Flacke, "Novel MRI Contrast Agent for Molecular Imaging of Fibrin Implications for Detecting Vulnerable Plaques," Circulation, Vol. 104, 1280-1285, (2001).
✓	BZ	E. Falk et al., "Coronary Plaque Disruption", Circulation, Vol. 92, 657, (1995).

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) (Title Amended 3/83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT-- <u>LIST OF ITEMS</u> (Use several sheets if necessary)				Applicant Egidijus Edward Uzgis et al.	
				Filing Date	
				Group	
OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc)					
✓	CU	S. Aime et al., "Insights Into the Use of Paramagnetic Gd (III) Complexes in MR-Molecular Imaging Investigations," Journal of Magnetic Resonance Imaging, Vol. 16, 394-406, (2002).			
✓	CV	R. Weissleder et al., "Molecular Imaging", Radiology, Vol. 219, 316-333, (2001).			
✓	CW	R. P. Choudhury et al., "MRI and Characterization of Atherosclerotic Plaque: Emerging Applications and Molecular Imaging," Arterioscler Thromb Vasc Biol., Vol. 22, 1065-1074, (2002).			
✓	CX	C. Casali et al., "Evaluation of Gd-DOTA-Labeled Dextran Polymer as an Intravascular MR Contrast Agent for Myocardial Perfusion," Acad. Radiol., Vol. 5 (Suppl. 1), S214-S218, (1998).			
✓	CY	P. Libby et al., "Inflammation an Atherosclerosis," Circulation, Vol. 105, 1135-1142, (2002).			
✓	CZ	C. R. Cantor et al., "Biophysical chemistry, Part II: Techniques for the Study of Biological Structure and Function," pp. 838-846, W. H. Freeman and Company, New York, New York (1980).			
✓	DU	C. R. Cantor et al., "Biophysical chemistry, Part III: The Behavior of Biological Macromolecules," pp. 979-1018, W. H. Freeman and Company, New York, New York (1980).			
✓	DV	P. J. Flory, "Statistical Mechanics of Chain Molecules," pp. 36-38, Oxford University Press, New York, New York (1989).			
	DW				
	DX				
	DY				
	DZ				
EXAMINER			DATE CONSIDERED		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>					